Physician profile
Lon A Castle
NPI 1972831469
$53,977.16
in general payments reported to CMS, 2019-2025
9 companies · $9,611 in 2025
The $9,611 reported for 2025 was more than what 98% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,966 · 2020: $2,299 · 2021: $7,636 · 2022: $15K · 2023: $3,907 · 2024: $11K · 2025: $9,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,407 · Travel and Lodging: $1,145 · Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,420.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,407.04 |
| Travel and Lodging | $1,144.63 |
| Food and Beverage | $421.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $21,868.91 | 2019-2024 | Voxzogo 1.2mg |
| Gen-Probe, INC. | $12,124.20 | 2021-2025 | Aptima, None |
| Roche Diagnostics Corporation | $7,527.61 | 2022 | |
| Johnson & Johnson Health Care Systems INC. | $7,111.02 | 2025 | |
| Amgen INC. | $2,000.00 | 2024 | Lumakras |
| Astrazeneca Pharmaceuticals LP | $1,536.00 | 2020 | |
| Hologic Sales and Service, LLC | $867.95 | 2024 | Btx, Aptima |
| Cepheid | $762.50 | 2020 | |
| Abbott Laboratories | $178.97 | 2024 | Ensite Precision |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lon Castle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.